Cargando…

Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting

INTRODUCTION: At the time of dapagliflozin’s approval in Europe (2012) to treat patients with type 2 diabetes mellitus, concerns regarding acute liver injury and severe complications of urinary tract infection (sUTI) led to two post-authorization safety (PAS) studies of these outcomes to monitor the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Danysh, Heather E., Johannes, Catherine B., Beachler, Daniel C., Layton, J. Bradley, Ziemiecki, Ryan, Arana, Alejandro, Dinh, Jade, Li, Ling, Calingaert, Brian, Pladevall-Vila, Manel, Hunt, Phillip R., Chen, Hungta, Karlsson, Cecilia, Johnsson, Kristina, Gilsenan, Alicia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883309/ https://www.ncbi.nlm.nih.gov/pubmed/36583828 http://dx.doi.org/10.1007/s40264-022-01262-4

Ejemplares similares

Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting
por: Johannes, Catherine B., et al.
Publicado: (2022)

Birth prevalence of phenylalanine hydroxylase deficiency: a systematic literature review and meta-analysis
por: Foreman, Pamela K., et al.
Publicado: (2021)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes
por: Mathieu, Chantal, et al.
Publicado: (2018)

Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies
por: Pladevall, Manel, et al.
Publicado: (2016)

Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride
por: Ruigómez, Ana, et al.
Publicado: (2021)

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Yavin, Yshai, et al.
Publicado: (2016)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
por: Ptaszynska, Agata, et al.
Publicado: (2015)

The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies
por: Varas-Lorenzo, Cristina, et al.
Publicado: (2014)

Dapagliflozin in patients with COVID-19: mind the kidneys – Authors' reply
por: Kosiborod, Mikhail N, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom
por: Willame, Corinne, et al.
Publicado: (2016)

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment
por: van der Walt, J-S, et al.
Publicado: (2013)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Development of a Conceptual Model of Adherence to Oral Anticoagulants to Reduce Risk of Stroke in Patients with Atrial Fibrillation
por: Brown, T. Michelle, et al.
Publicado: (2012)

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
por: Sonesson, Christian, et al.
Publicado: (2016)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
por: Fioretto, Paola, et al.
Publicado: (2016)

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
por: Stack, Austin G, et al.
Publicado: (2020)

Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350
por: Fortuny, Joan, et al.
Publicado: (2019)

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
por: Koshino, Akihiko, et al.
Publicado: (2023)

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
por: Han, Eugene, et al.
Publicado: (2018)

Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
por: Fioretto, Paola, et al.
Publicado: (2016)

Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus
por: Chen, Ying-Ying, et al.
Publicado: (2019)

Not so critical appraisal of dapagliflozin
por: Doggrell, Sheila A
Publicado: (2014)

Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
por: Johansson, Lars, et al.
Publicado: (2020)

Triple therapy with low‐dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2019)

Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study
por: Alguwaihes, Abdullah M.
Publicado: (2021)

Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies
por: Mitchell, S., et al.
Publicado: (2016)

Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study
por: Gilsenan, Alicia, et al.
Publicado: (2019)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

An exploration of the experience of dapagliflozin in clinical practice
por: Anitha, Anuba Paulvarnan, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16‐week double‐blind treatment period
por: Araki, Eiichi, et al.
Publicado: (2016)

Author Response: Surface Area of the Exposed Eye
por: Glasgow, Ben J.
Publicado: (2021)

Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
por: Lundkvist, Per, et al.
Publicado: (2017)

Dapagliflozin-Induced Acute-on-Chronic Liver Injury
por: Levine, Joshua A., et al.
Publicado: (2016)

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e3n1qu8uns5kj90rm97idr3k0o